Pfiz­er’s gam­ble on a new lease on life for ag­ing silde­nafil fran­chise fiz­zles in PhI­II

Pfiz­er took a Phase III shot at re­pur­pos­ing its old drug silde­nafil as a new com­bi­na­tion ther­a­py for per­sis­tent pul­monary hy­per­ten­sion in in­fants. And failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER